Business Description
Aerovate Therapeutics Inc
NAICS : 541713
SIC : 2834
ISIN : US0080641071
Description
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 181.39 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 56.1 | |||||
| 3-Year EPS without NRI Growth Rate | 58.3 | |||||
| 3-Year FCF Growth Rate | 59.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 15.4 | |||||
| 9-Day RSI | 28.06 | |||||
| 14-Day RSI | 36.42 | |||||
| 6-1 Month Momentum % | 126.21 | |||||
| 12-1 Month Momentum % | 41.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.04 | |||||
| Quick Ratio | 7.04 | |||||
| Cash Ratio | 6.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.8 | |||||
| Shareholder Yield % | 0.03 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -61.21 | |||||
| ROA % | -55.23 | |||||
| ROIC % | -1839.75 | |||||
| ROC (Joel Greenblatt) % | -7528.11 | |||||
| ROCE % | -65.69 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 5.6 | |||||
| Price-to-Tangible-Book | 5.6 | |||||
| EV-to-EBIT | -5.9 | |||||
| EV-to-EBITDA | -5.91 | |||||
| EV-to-FCF | -8.44 | |||||
| Price-to-Net-Current-Asset-Value | 5.76 | |||||
| Price-to-Net-Cash | 5.86 | |||||
| Earnings Yield (Greenblatt) % | -16.95 | |||||
| FCF Yield % | -9.26 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AVTE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aerovate Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.88 | ||
| Beta | 0 | ||
| Volatility % | 84.67 | ||
| 14-Day RSI | 36.42 | ||
| 14-Day ATR ($) | 2.129898 | ||
| 20-Day SMA ($) | 26.8155 | ||
| 12-1 Month Momentum % | 41.63 | ||
| 52-Week Range ($) | 9.41 - 32.415 | ||
| Shares Outstanding (Mil) | 27.86 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aerovate Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aerovate Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Aerovate Therapeutics Inc Frequently Asked Questions
What is Aerovate Therapeutics Inc(AVTE)'s stock price today?
The current price of AVTE is $22.05. The 52 week high of AVTE is $32.42 and 52 week low is $9.41.
When is next earnings date of Aerovate Therapeutics Inc(AVTE)?
The next earnings date of Aerovate Therapeutics Inc(AVTE) is 2024-05-15 Est..
Does Aerovate Therapeutics Inc(AVTE) pay dividends? If so, how much?
Aerovate Therapeutics Inc(AVTE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers